Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  PureTech Health plc    PRTC   GB00BY2Z0H74

PURETECH HEALTH PLC

(PRTC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
381.5(c) 383(c) 397(c) 392(c) 389.5(c) Last
79 082 109 436 214 915 178 129 194 938 Volume
0.00% +0.39% +3.66% -1.26% -0.64% Change
More quotes
Financials (USD)
Sales 2020 14,2 M - -
Net income 2020 94,3 M - -
Net Debt 2020 3,05 M - -
P/E ratio 2020 43,6x
Yield 2020 -
Sales 2021 11,1 M - -
Net income 2021 -124 M - -
Net cash position 2021 76,6 M - -
P/E ratio 2021 -3,19x
Yield 2021 -
Capitalization 1 523 M 1 521 M -
EV / Sales 2020 108x
EV / Sales 2021 130x
Nbr of Employees 300
Free-Float 84,2%
More Financials
Company
PureTech Health PLC is a clinical stage biotechnology company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a... 
More about the company
Notations Surperformance© of PureTech Health plc
Trading Rating : Investor Rating :
More Ratings
All news about PURETECH HEALTH PLC
01/15PURETECH HEALTH : SVB Leerink Initiates Coverage on PureTech Health With Outperf..
MT
01/14PURETECH HEALTH : Vor Biopharma Gets IND Clearance From FDA for Clinical Trial o..
MT
01/14PURETECH HEALTH : Founded Entity Vor Announces FDA Clearance of IND Application ..
BU
01/14PURETECH HEALTH : Founded Entity Follica Adds Two Leaders in Aesthetic Medicine ..
BU
01/14PURETECH HEALTH : Follica Adds Two Leaders in Aesthetic Medicine and Dermatology..
BU
01/12PureTech Founded Entity Vedanta Biosciences Receives $25 Million Investment F..
MT
01/12VEDANTA BIOSCIENCES : Announces $25 Million Investment from Pfizer Inc.
BU
01/12PURETECH HEALTH : Founded Entity Vedanta Biosciences Announces $25 Million Inves..
BU
01/05PURETECH HEALTH : Appoints George Farmer Chief Financial Officer
MT
01/05PURETECH HEALTH : Announces the Appointment of George Farmer, Ph.D., as Chief Fi..
BU
2020PURETECH HEALTH : to Present at 38th Annual J.P. Morgan Healthcare Conference an..
BU
2020PURETECH HEALTH : Initiates Phase 1 Trial of LYT-200 to Treat Solid Tumors
MT
2020PURETECH HEALTH : Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for..
BU
2020PURETECH HEALTH : Starts Proof-Of-Concept Trial in Breast Cancer-Related Lymphed..
MT
2020PURETECH HEALTH : Initiates Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphe..
BU
More news
News in other languages on PURETECH HEALTH PLC
2020PURETECH HEALTH PLC : Veröffentlichung des Jahresergebnisses
2020PURETECH HEALTH PLC : publication des résultats annuels
2020AVIS D'ANALYSTES DU JOUR : BNP Paribas, LVMH, L'Oréal, Vallourec, Nexans, Sunris..
2020STOCK MARKET PARIS : Coronavirus, peur sur l'économie
2018ERRATA CORRIGE : Pubblicati sulla rivista Obesity i dati principali sulla perdit..
More news
Analyst Recommendations on PURETECH HEALTH PLC
More recommendations
Chart PURETECH HEALTH PLC
Duration : Period :
PureTech Health plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PURETECH HEALTH PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 6,33 $
Last Close Price 5,33 $
Spread / Highest target 20,0%
Spread / Average Target 18,8%
Spread / Lowest Target 17,9%
EPS Revisions
Managers and Directors
NameTitle
Daphne Zohar Chief Executive Officer & Executive Director
Bharatt M. Chowrira President, Chief Business & Strategy Officer
Christopher A. Viehbacher Chairman
Stephen Muniz Chief Operations Officer, Secretary & Director
George Farmer Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
PURETECH HEALTH PLC-2.63%1 521
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059